Black Diamond director granted 40,000 stock options

Black Diamond Therapeutics director Shannon Campbell received a grant of stock options covering 40,000 shares of common stock.

Rhea-AI Filing Summary

Black Diamond Therapeutics director Shannon Campbell received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036.

According to the terms, the entire option grant will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Campbell continues to serve through that date. Following this grant, Campbell holds options for 40,000 underlying shares directly.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Campbell Shannon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 40,000 shares Exercise price: $1.71 per share Underlying shares: 40,000 shares +3 more

6 metrics

Option grant size 40,000 shares Stock Option (Right to Buy) granted to director

Exercise price $1.71 per share Conversion or exercise price of stock option

Underlying shares 40,000 shares Common stock underlying the option

Total options after grant 40,000 shares Total shares following transaction, held directly

Expiration date June 25, 2036 Option term end date

Vesting date trigger June 26, 2027 Earlier of this date or next annual meeting, subject to service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.7100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Black Diamond Therapeutics (BDTX) director Shannon Campbell report on this Form 4?

Shannon Campbell reported receiving a grant of stock options for 40,000 shares of Black Diamond Therapeutics common stock. The options are a compensation-related award, not an open-market purchase, and were reported as an acquisition of derivative securities on the Form 4.

What is the exercise price of Shannon Campbell’s new Black Diamond (BDTX) stock options?

The granted stock options have an exercise price of $1.71 per share. This means Campbell can, once vested, buy Black Diamond Therapeutics common stock at $1.71 per share regardless of the future market price, until the options expire.

When do Shannon Campbell’s Black Diamond Therapeutics (BDTX) options vest?

The options vest and become exercisable in full on the earlier of June 26, 2027, or Black Diamond Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on Campbell’s continued service with the company through the applicable vesting date.

When do the newly granted Black Diamond (BDTX) stock options expire?

The options are scheduled to expire on June 25, 2036. After this expiration date, Campbell would no longer be able to exercise the options to purchase Black Diamond Therapeutics common stock at the $1.71 exercise price.

How many Black Diamond Therapeutics (BDTX) shares are covered by Shannon Campbell’s new option grant?

The option grant covers 40,000 shares of Black Diamond Therapeutics common stock. Following this grant, Campbell’s reported holdings include options representing 40,000 underlying shares, all held directly as reported on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Shannon

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

ONE MAIN STREET, 14TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.71	06/26/2026		A		40,000		(1)	06/25/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)